About Sanity

Sanity Group develops cannabinoid-based pharmaceuticals and wellness products that utilize precise extraction methods to ensure consistent dosing and efficacy. The company addresses the need for reliable therapeutic options in the growing market for cannabinoid treatments.

<problem> The European market for cannabinoid-based therapies faces challenges due to varying regulations, healthcare systems, and a historical research backlog regarding the therapeutic potential of cannabis. This results in inconsistent access to reliable cannabinoid treatments and wellness products across different regions. </problem> <solution> Sanity Group addresses these challenges by developing and distributing cannabinoid-based pharmaceuticals and wellness products tailored to the specific needs of the European market. The company focuses on research and development, utilizing precise extraction methods to ensure consistent dosing and efficacy. Through its Sanity Medical division, the company develops and distributes innovative cannabis pharmaceuticals, while Sanity Care focuses on superior consumer products based on non-psychoactive cannabinoids. Sanity Science conducts R&D and produces high-quality extracts for all operational business areas. </solution> <features> - Development of cannabinoid-based pharmaceuticals adhering to GMP standards - Distribution of medicinal cannabis products to pharmacies and clinical institutions through Vayamed - Development of consumer CBD products through vaay - R&D projects focused on exploring the therapeutic potential of cannabinoids - High-quality cannabinoid extracts for pharmaceutical and consumer applications - Medical and political advisory boards to inform strategic direction and address perception issues - Partnerships with production facilities in Europe, South Africa, and Canada </features> <target_audience> Sanity Group targets patients seeking cannabinoid-based therapies, healthcare professionals, and consumers interested in cannabinoid-based wellness products in the European market. </target_audience>

What does Sanity do?

Where is Sanity located?

Sanity is based in Berlin, Germany.

When was Sanity founded?

Sanity was founded in 2018.

How much funding has Sanity raised?

Sanity has raised $130.6M.

Who founded Sanity?

Sanity was founded by Finn Hänsel.

Finn Hänsel - CEO & Founder

Location

Berlin, Germany

Founded

2018

Funding

$130.6M

Employees

82 employees

Investors

Cherry Ventures Seven Ventures Tq TQ Ventures

Sanity

Berlin, GermanyFounded 2018827K+ followers10/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.

Updated 18 months ago

Funding

$130.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

The European market for cannabinoid-based therapies faces challenges due to varying regulations, healthcare systems, and a historical research backlog regarding the therapeutic potential of cannabis. This results in inconsistent access to reliable cannabinoid treatments and wellness products across different regions.

Solution

Sanity Group addresses these challenges by developing and distributing cannabinoid-based pharmaceuticals and wellness products tailored to the specific needs of the European market. The company focuses on research and development, utilizing precise extraction methods to ensure consistent dosing and efficacy. Through its Sanity Medical division, the company develops and distributes innovative cannabis pharmaceuticals, while Sanity Care focuses on superior consumer products based on non-psychoactive cannabinoids. Sanity Science conducts R&D and produces high-quality extracts for all operational business areas.

Target Audience

Sanity Group targets patients seeking cannabinoid-based therapies, healthcare professionals, and consumers interested in cannabinoid-based wellness products in the European market.

Features

Development of cannabinoid-based pharmaceuticals adhering to GMP standards
Distribution of medicinal cannabis products to pharmacies and clinical institutions through Vayamed
Development of consumer CBD products through vaay
R&D projects focused on exploring the therapeutic potential of cannabinoids
High-quality cannabinoid extracts for pharmaceutical and consumer applications
Medical and political advisory boards to inform strategic direction and address perception issues
Partnerships with production facilities in Europe, South Africa, and Canada